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Glasgow, United KingdomAdenosine is a ubiquitous extracellular signaling molecule with essential functions in human physiology.
Due to the widespread expression of adenosine receptors, it has far-reaching effects across many different
organ systems. With a prominent role in the cardiovascular system, it has been extensively studied for
both its therapeutic and diagnostic abilities. One of the key areas of use is in the coronary circulation
whereby adenosine produces a hyperemic response. An important target of adenosine is the coronary
microcirculation whereby adenosine acts as a prominent vasodilator with many of the beneﬁcial effects of
adenosine reﬂected in its capacity to affect the microvessels. Adenosine also has an important role in the
pre-conditioned state and also in the attenuation of ischemia-reperfusion injury. This review examines
the physiology, pharmacology, and therapeutic applications of adenosine in the human cardiovascular
system and provides a brief overview of important aspects of the adenosine-cardiac interaction. It also
examines the role of adenosine in the coronary hyperemic response and discusses the use of adenosine
for this purpose. After recent concerns about the use of adenosine, a discussion regarding safety of this
drug is provided. A brief review of novel agents used to initiate coronary hyperemia is also provided.
(J Am Coll Cardiol Intv 2014;7:581–91) ª 2014 by the American College of Cardiology FoundationAdenosine is a ubiquitous extracellular signaling
molecule with essential functions in human physi-
ology. From providing the backbone for basic en-
ergy transfer through its adenosine triphosphate
(ATP) and adenosine diphosphate interactions to
its role in cell signaling, adenosine is a fundamental
component of human biology (1). Adenosine has
far-reaching effects as an extracellular signaling
molecule inducing vasodilation in most vascular
beds, regulating activity in the sympathetic nervous
system, having antithrombotic properties, and re-
ducing blood pressure and heart rate. Such prop-
erties are some of the reasons why adenosine and its
derivatives have therapeutic effects in most organ
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much of our understanding of adenosine has come
through observations of its action in the cardio-
vascular system. Pioneering work by Drury and
Szent-Gyorgyi (2) in the past century pointed to
the fact that an adenine compound caused distur-
bances in heart rate when injected intravenously. It
is likely that this adenine compound was in fact
adenosine. However, it was not until w60 years
later that the use of this property of adenosine was
used clinically to treat patients presenting with
supraventricular tachycardia (3).
One of the most common reasons for using aden-
osine in the cardiovascular system is for the produc-
tion of vasodilation in the coronary microcirculation
to produce hyperemia (4). This property of adenosine
to modify microcirculatory function has been used
for diagnostic and therapeutic effects for many years
and is widely adopted as the gold-standard method
of diagnosing ischemia invasively and noninvasively.
This review examines the physiology, pharma-
cology, and therapeutic applications of adenosine in
the human cardiovascular system and provides a
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582brief overview of important aspects of the adenosine-cardiac
interaction.
Adenosine Pharmacology
Adenosine is a naturally occurring endogenous purine nu-
cleoside composed of an adenine molecule attached to a
ribose sugar moiety (1) (ribofuranose) via a beta-N9-glycosidic
bond (6-amino-9-b-D-ribofuranosyl-9-H-purine) (Fig. 1). It
is the nucleoside base of both ATP and the signaling
molecule cyclic adenosine monophosphate (cAMP). Aden-
osine is rapidly transported into vascular endothelial cells
and erythrocytes where it is catabolized by adenosine
deaminase to inosine (5). Dipyridamole, a commonly used
vasoactive medication (6) exerts its effects through inhibition
of adenosine deaminase. Adenosine is (re)phosphorylated by
adenine kinase forming adenosine monophosphate, which is
incorporated into the high-energy phosphate pool (7).Abbreviations
and Acronyms
AF = atrial ﬁbrillation
ATP = adenosine
triphosphate
AV = atrioventricular
cAMP = cyclic adenosine
monophosphate
FFR = fractional ﬂow reserve
IC = intracoronary
IV = intravenous
PCI = percutaneous coronary
intervention
STEMI = ST-segment
elevation myocardial
infarctionAdenosine levels can rise rapidly
in ischemic tissue due to adeno-
sine kinase inhibition (1).
In the intracellular space,
adenosine can be synthesized de
novo during purine biosynthesis
or accumulate as a result of ATP
breakdown. Intracellular adeno-
sine concentrations increase when
there is a mismatch between ATP
synthesis and use as in ischemia
or hypoxia (8,9). Adenosine does
not freely pass across the cell
membrane and requires the use
of nucleoside transporters to fa-
cilitate the process. Extracellular
adenosine arises from active trans-
port of intracellular stores or frombreakdown of adenine nucleotides outside the cell (1).
Adenosine binds with 4 evolutionary well-conserved re-
ceptor subtypes that are ubiquitously expressed: A1, A2A,
A2B, and A3 (10,11). These receptors interact with G-pro-
tein receptors. Activation of the Gi protein–bound A1 and
A3 receptors reduces adenyl cyclase activity and decreases
intracellular cAMP. Activation of the Gs protein–bound
A2A and A2B receptors increases adenyl cyclase activity and
cAMP levels. Adenosine has highest afﬁnity for the A1 and
A2a receptors.
Activation of A2A and A2B adenosine receptors produces
potent vasodilation of most vascular beds including the
coronary circulation, resulting in an increase in myocardial
blood ﬂow (12). However, A2A and A2B activation pro-
duces vasoconstriction in renal (13) and splenic afferent
arterioles and hepatic veins.
A1 receptors generally have an inhibitory function on
most tissues. Activation of cardiac A1 receptors has amyocardial depressant effect with negative chronotropic and
dromotropic effects. A1 receptor activation also mediates
inhibition of atrioventricular (AV) node conduction and
prolongation of the refractory period via inhibition of
cAMP-mediated calcium inﬂux and enhances potassium
conduction (14) (Fig. 2).
A2A receptor activation also produces anti-inﬂammatory
effects and acts as a major target of caffeine. A2B receptors
are found on human mast cells and are thought to produce
mast cell degranulation and bronchial constriction (15). A3
receptors are mainly peripherally located but are thought to
play a role in mediating pre-conditioning.
The use of adenosine for stress testing and induction of
systemic (and coronary) hyperemia is primarily related to the
activation of A2A receptors and the resultant increase in
myocardial blood ﬂow.
The Human Coronary Microcirculation
and Adenosine
The coronary microcirculation is a key regulator of
myocardial blood ﬂow. Through alterations in microvascular
resistance, the microcirculation controls the delivery of blood
to the myocardium over a wide range of perfusion pressures
and myocardial oxygen demand through the process of
autoregulation (16). In humans, coronary blood ﬂow can
increase up to 5 times the basal ﬂow to meet increased
demand (17). Such an increase in blood ﬂow is referred to as
a hyperemic response and in humans is commonly observed
in response to ischemia and exercise (18,19). Quantifying
the hyperemic response is a critical step in understanding the
coronary circulation and is applied in most physiological
assessments of myocardial blood ﬂow. Maximal hyperemia
can be achieved through a variety of methods. Exercise is
commonly used, but the ability of some patients to exercise
is limited. Vessel occlusion to produce ischemia (20) (and
thus reactive hyperemia) is another method used in animal
models but is not practical or safe to be used in humans not
undergoing percutaneous coronary intervention (PCI) due to
the inherent risk of vessel injury. Pharmacologically induced
vasodilation is a commonly used method of achieving hy-
peremia in the noninvasive and catheter laboratory settings.
Available agents include adenosine, papaverine, sodium
nitroprusside, adenosine 50-triphosphate, and dobutamine
(Table 1). Practically, the ideal hyperemic agent should have
a rapid onset of action, short duration of action, low cost
with no signiﬁcant side effects (21). For these reasons,
adenosine, administered via either the intracoronary or IV
route, has become the most widely used method of achieving
hyperemia in clinical practice.
The Case for Adenosine
Despite extensive use of adenosine in animal experiments,
there was some reluctance to use it for interrogating the
Figure 1. The Metabolism of Adenosine
Schematic diagram to represent the intracellular and extracellular metabolism of adenosine. ADA ¼ adenosine deaminase (deamination); ADP ¼ adenosine 50-
diphosphate; AK ¼ adenosine kinase (phosphorylation); AMP ¼ adenosine 50-monophosphate; ATP ¼ adenosine 50-triphosphate; cAMP ¼ cyclic adenosine 30 ,50-
monophosphate; ENPP2 ¼ ecto-nucleotide pyrophosphatase/phosphodiesterase; ENTPDase ¼ ecto-nucleoside triphosphate diphosphohydrolase; ENTs¼ equilibrative
nucleoside transporters; HGPRT ¼ hypoxanthine phosphoribosyl transferase; IMP ¼ inosine 50-monophosphate; NDP ¼ nucleoside diphosphate; 50-NT ¼ 50-nucleo-
tidase (dephosphorylation); PDE ¼ phosphodiesterase; PNP ¼ purine nucleoside phosphorylase; SAH ¼ S-adenosylhomocysteine; XO ¼ xanthine oxidase.
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583human coronary circulation due to concerns over hypoten-
sion and heart block. However, work performed by Wilson
et al. and others (22,23) and others demonstrated that the
use of adenosine was safe via both the intracoronary and IV
routes and that it could reliably induce near-maximal coro-
nary hyperemia in most patients with little effect on systemic
blood pressure. Although it was evident that adenosine
produced coronary microcirculatory vasodilation, the exact
mechanism of action remained incompletely understood.
Functional and anatomic aspects of hyperemia. The
coronary circulation can be thought of in terms of a
3-compartment model, each of which contributes to the
overall resistance to ﬂow. The large epicardial vessels (0.5- to
5.0-mm diameter) make up the ﬁrst compartment (R1) and
divide into progressively smaller branches known as theresistance microvessels (24). This second compartment (R2)
consists of small coronary arteries/pre-arterioles (100- to
500-mm diameter) and arterioles (<100-mm diameter),
which branch into intramyocardial capillaries to create the
third compartment (R3). Ultimately, these drain into the
coronary venous system (25). Under nonpathological resting
conditions, the epicardial vessels offer little resistance to
coronary ﬂow, acting as passive conduits only. Approxi-
mately 60% of resistance is provided at the arteriolar level,
25% at the capillary level, and the remaining 15% in the
venular compartment (26). During hyperemia, total resis-
tance decreases across the coronary circulation byw70%. In
the arteriolar and venular compartments, resistance decreases
by 86% and 98%, respectively, resulting in minimal alter-
ation of capillary hydrostatic pressure such that the
Figure 2. The Cardiovascular Effects of Adenosine
Simpliﬁed diagram providing common sites for adenosine and adenoreceptor interaction in the cardiovascular system. AVN ¼ atrioventricular node;
SAN ¼ sinoatrial node.
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584capillaries offer the most resistance to coronary blood ﬂow at
hyperemia. Thus, the capillaries provide the ceiling for the
hyperemic response (27).
Adenosine exerts its predominant vasodilatory effect on
coronary microvessels <150 mm in diameter (28). Whether
this is an endothelium-dependent process is unclear. An
intact endothelium is not necessary for an adenosine res-
ponse in vitro (29). However, work performed in humans
in vivo has demonstrated that the vasodilator effect of
adenosine in the forearm can be inhibited by a nitric oxide
synthase inhibitor (30).
For the assessment of coronary stenoses, the effect of
adenosine on the coronary microcirculation is to produce
vasodilation to counteract the inﬂuence of autoregulation
and ensure that resistance is minimal. In the assessment of
fractional ﬂow reserve (FFR), the use of adenosine in this
manner allows for a near-linear relationship between pres-
sure and ﬂow to be achieved. However, in the presence of
severe stenoses, some have argued that there is a limited
vasodilatory response to adenosine such that basal ﬂow may
equal hyperemic ﬂow (31). However, others have shown in
animal models that even in the presence of severe stenosis,
there exists some retention of vasodilatory capacity of themicrocirculation to adenosine (32). Regardless, it is of
limited clinical importance because in most catheter labo-
ratory settings, the FFR is really only used for intermediate
stenoses (40% to 70%).
Adenosine is widely available worldwide and relatively in-
expensive, producing stable and reproducible effects, hence,
its increasing use in both diagnostic and interventional car-
diology over the past 20 years. Furthermore, the availability
of pre-made adenosine infusion bags that are stable at room
temperature and suitable for short-term storage adds to its
appeal (33).
Methods of Administration
The most common method of administration is the IV route
frequently used for the termination of AV node–dependent
tachycardias and for the attainment of hyperemia in
noninvasive stress testing. In the context of achieving
maximal hyperemia in the catheter laboratory, both the
intracoronary (IC) and intravenous (IV) routes are used.
IC adenosine. IC administration of adenosine is simple and
quick. Its peak effect occurs <10 s after administration, and
it has a duration ofw20 s (34). For this reason, the IC route
Table 1. Agents Used for Hyperemia (Invasive and Noninvasive)
Drug (Ref #) Route of Administration Dose Side Effect Comment
Nitroprusside (100) IC 0.6 mg/kg Decrease in systemic blood pressure,
nausea, headache
Longer duration of action than IC adenosine.
Suboptimal hyperemic response compared
with IV adenosine. May be useful in patients
with contraindication to adenosine
(e.g., asthma).
Dypridamole (101) IV 142 mg/kg/min Headache, nausea, ﬂushing Inhibits cellular uptake of adenosine and
adenosine degradation. Used for noninvasive
diagnostic tests. No evidence with invasive
coronary assessment.
Dobutamine (102) IV 5–40 mg/kg/min Tachycardia, tachyarrhythmia,
chest pain, hypertension
Efﬁcacy similar to that of dipyridamole in
noninvasive testing when combined with
atropine. Not used in catheter laboratory,
mainly for noninvasive studies. Not
recommended for invasive assessment of FFR.
Adenosine 50-triphosphate (37,38) IV vs. IC 140 mg/min/kg Bronchospasm, AV block Efﬁcacy similar to that of adenosine but limited
availability
Papaverine (45,103) IC 12–16 mg RCA,
16–20 mg LCA
QT interval prolongation, increase
in coronary venous lactate
Can produce steady-state hyperemia for FFR
pull-back assessment. Correcting potassium
and ensuring that no other QT interval–
prolonging drugs are being taken can
minimize the risk of arrhythmia.
AV ¼ atrioventricular; FFR ¼ fractional ﬂow reserve; IC ¼ intracoronary; IV ¼ intravenous; LCA ¼ left coronary artery; RCA ¼ right coronary artery.
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585is not used in cases in which a longer period of steady-state
hyperemia is required such as when performing an FFR
pullback or more complex assessments of microvascular
function (35). Earlier studies had suggested a maximal IC
dose of adenosine of 16 mg for the left coronary artery and
12 mg for the right coronary artery (22) with increasing doses
of 2 orders of magnitude to ensure maximal vasodilation
(36). These protocols were challenged by animal data sug-
gesting that higher doses of adenosine may be needed to
achieve maximal hyperemia (37,38) and clinical studies
that suggested that standard adenosine dosing failed to
achieve maximal hyperemia compared with papaverine and
IV adenosine (22,38). Current recommendations for IC
adenosine dosing are 40 mg in the right coronary artery and
60 mg in the left coronary artery, increasing the doses
incrementally by 30 mg to a maximum of 150 mg (39). We
suggest a higher bolus dose of IC adenosine (100–150 mg) to
ensure an adequate hyperemic response.
Whether the IC route is as efﬁcacious at producing
maximal hyperemia compared with the IV route is a
controversial area that has been addressed in several clinical
studies. The lower efﬁcacy of IC adenosine compared with
IV adenosine was highlighted in a study by Casella et al.
(40). They compared the effects of IC versus IV adenosine
in 50 stable patients; 60 mg of adenosine was used with
increasing doses up to 150 mg. At the lower, “standard”
doses, 10% of vessels with an initial FFR value >0.75 had a
subsequent value less than this cutoff point with higher
IC doses or IV administration.
Leone et al. (41) also examined the dose-response of IC
adenosine compared with IV adenosine. They demonstratedthat only the higher doses of IC adenosine (600 mg) pro-
duced hyperemic efﬁcacy similar to that of IV adenosine and
that standard dosing (60 to 300 mg) with IC adenosine was
not sufﬁcient. Importantly, lower doses of adenosine were
associated with inferior diagnostic accuracy compared with
IV adenosine. However, at higher doses of IC adenosine,
transient AV block developed in nearly 25% of patients.
De Luca et al. (42) demonstrated similar results in 46
patients with intermediate coronary stenoses undergoing di-
agnostic FFR evaluation. They showed that FFR values pro-
gressively decreased with increasing doses of IC adenosine up
to 720 mg. With this, the number of patients identiﬁed with
FFR values<0.75 increased. Of interest, and in contradiction
to Leone et al. (41), increasing the adenosine dose did not
increase the incidence of side effects, which was very low.
Thus, it appears from studies to date that the IV route of
administration has a greater efﬁcacy for achieving maximal
hyperemia compared with the conventional IC dosing with
the added advantage that FFR pullback and more complex
physiological assessments can be made. Furthermore, stan-
dard adenosine dosing may not be sufﬁcient to produce a
hyperemic response, and higher does may be required.
Central versus peripheral route of administration. Central
venous infusion of adenosine through the femoral vein has
been the gold-standard method of hyperemia induction,
particularly in the assessment of FFR (43). However, it re-
quires femoral vein access and is inconvenient during
transradial catheterization, which is an increasingly preferred
method of arterial access. In a study by Seo et al. (44),
involving 71 patients, no difference was found in the
hyperemic efﬁciency of IV administration of adenosine via
Layland et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 7 , N O . 6 , 2 0 1 4
Adenosine Review J U N E 2 0 1 4 : 5 8 1 – 9 1
586the forearm compared with the femoral vein. The number of
functionally signiﬁcant stenoses (FFR <0.75) was also not
different between the 2 routes, and there was no difference
between the hyperemic mean transit time and index of
microcirculatory resistance, suggesting that minimal resis-
tance and thus maximal hyperemic response was achieved
with both routes of administration. Consistent with these
ﬁndings, De Bruyne et al. (45) showed that the hyperemic
efﬁcacy of adenosine was similar in both central and peri-
pheral venous infusions, and increasing the dose to >140
mg/kg/min did not improve the vasodilatory action of
adenosine. In both of these studies, the time to maximal
hyperemia was longer with forearm vein infusion of aden-
osine than with the femoral vein infusion, with a mean
difference of w15 s, suggesting that when a peripheral
venous route is selected, adenosine should be infused for a
greater length of time.
In contrast to these ﬁndings, Lindstaedt et al. (46) com-
pared the hyperemic efﬁcacy of adenosine infusion between
the femoral vein and the antecubital vein in 50 patients and
reported that a 140-mg/kg/min infusion of adenosine via the
antecubital vein was slightly less effective than the femoral
vein infusion with a higher frequency of lesion severity un-
derestimation. However, the mean FFR difference between
the 2 routes was only 0.013. Of interest, the group admin-
istered adenosine at higher doses (170 mg/kg/min) periph-
erally and found no difference in hyperemic efﬁcacy
compared with the femoral route. For this reason, they rec-
ommended administering a higher dose of adenosine via the
antecubital vein to achieve hyperemic efﬁcacy similar to that
via the femoral route.
The concept of increasing the dose of adenosine to improve
hyperemic efﬁcacy appears intuitive. However, unlike the
ﬁndings of Lindstaedt et al. (46) described previously, other
groups have not found such a relationship. In 1 study, the
addition of an additional IC bolus of adenosine did not
result in any change in FFR compared with standard aden-
osine infusion, although it did increase the incidence of
transient AV block (44). These ﬁndings were in agreement
with other investigators who also showed no evidence of
any change in FFR with doses of up to 240 mg/kg/min (45).
We recommend the use of IV adenosine at a dose of
140 mg/kg/min and either the peripheral (via a large-caliber
vein) or central route depending on operator preference. If
using the peripheral route, it may take longer for a hyperemic
response to develop, and thus a longer infusion time may be
required. Furthermore, if the FFR is borderline, higher doses
of adenosine may be used, but we do not advocate this for all
patients.
During the initial phase of adenosine infusion, there can
be differential changes to proximal and distal coronary
pressure such that the FFR value may ﬂuctuate during this
period. This is a critical point because, if FFR values are
taken without the attainment of steady-state hyperemia, thevalue may be inaccurate and lead to incorrect assumptions
regarding the hemodynamic signiﬁcance of a lesion.
Adenosine in the setting of myocardial infarction and
reperfusion. There is a strong body of experimental evi-
dence to suggest that adenosine can protect the myocardium
from both ischemic (47–49) and reperfusion injury via its
potent vasodilatory effects and possibly by anti-inﬂammatory
and antiplatelet properties (49,50). However, clinical studies
with adenosine in humans have yielded mixed results. IV
adenosine during primary PCI was tested in 2 large ran-
domized trials (51,52) (AMISTAD I and II, including 218
and 2,118 patients, respectively). Both of these trials
demonstrated that adenosine reduced infarct size, but did
not reduce the primary clinical endpoint, with in-hospital
and 6-month clinical outcome being similar to those in the
placebo group. However, in a post-hoc subgroup analysis, a
beneﬁt was seen in those receiving reperfusion therapy
within 3 h (53). These data are consistent with the results of
a small trial of IC infusion of adenosine in patients with
acute ST-segment elevation myocardial infarction (STEMI)
undergoing primary angioplasty, which showed favorable
effects on the incidence of no-reﬂow, left ventricular ejection
fraction, and clinical course (54). Improved myocardial
reperfusion, as assessed by ST-segment elevation resolution
after primary PCI, was observed in other smaller studies
(55,56). Conversely, a randomized, placebo-controlled trial
of 112 patients found no evidence that selective high-dose
IC administration of adenosine distal to the occlusion site in
the culprit vessel in STEMI patients resulted in any incre-
mental myocardial salvage or reduction in microvascular
obstruction (57). In addition, a single-blind study of 448
STEMI patients randomized to 2 bolus injections of IC
adenosine (2  120 mg) or matching placebo after manual
thrombus aspiration failed to show any difference in the
primary endpoint of residual ST-segment elevation after
primary PCI (58). Recently, these data were again tested in a
randomized study comparing adenosine, nitroprusside, and
saline solution. The use of 120 mg of adenosine as a bolus
followed by 2 mg administered in 33-ml of saline solution
over 2 min as a slow bolus was associated with improved
ST-segment elevation resolution on electrocardiography but
not angiographic microvascular obstruction or major adverse
cardiac events (59). Despite these mixed ﬁndings, IC aden-
osine is recommended by both the European Society of
Cardiology (60) and the American Heart Association (61)
guidelines for the treatment of no-reﬂow.
Pre- and post-conditioning. Transient episodes of ischemia
render the myocardium more resistant to subsequent is-
chemia, a phenomenon known as ischemic pre-conditioning
(62). This effect is thought to be partly mediated by
endogenous adenosine. The pre-conditioned state is trig-
gered through activation of A1 and A3 receptors by aden-
osine before the onset of ischemia (63,64). Pre-conditioning
has been shown to improve outcomes in patients
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587undergoing coronary artery bypass graft and elective PCI
(65,66). In a small study of 30 patients undergoing PCI,
Leesar et al. (67) demonstrated that a 10-min IV adenosine
infusion (dose of 2 mg/min) administered before the PCI
pre-conditioned the myocardium (67). However, among
stable elective patients undergoing PCI, the randomized
administration of 120 mg and 180 mg of adenosine into the
right and left coronary arteries, respectively, was not associ-
ated with a reduction of periprocedural myocardial infarction,
Thrombolysis In Myocardial Infarction frame count, or
in-hospital death (68).
For obvious reasons, ischemic pre-conditioning is limited
to patients who are due to have planned ischemia as in the
case of coronary artery bypass graft and PCI.
Post-conditioning refers to a time-sensitive cardiopro-
tective strategy induced by brief repetitive interruptions in
blood ﬂow applied immediately at the onset of reperfusion
(69). Evidence suggests that, like pre-conditioning, post-
conditioning involves endogenous activation of A2a and
A3 receptor subtypes. Several small studies on acute STEMI
patient groups have shown a cardioprotective effect of post-
conditioning (70). Hahn et al. (71), using a protocol that
consisted of 4 cycles of 1 min of balloon inﬂation followed
by 1 min of balloon deﬂation within 1 min of reﬂow after
coronary stent deployment, demonstrated that patients
in the post-conditioning group were found to have 36%
smaller infarctions as determined by serum creatine kinase
release during the ﬁrst 72 h of reperfusion and lower peak
creatine kinase. However, the recent POST (Ischemic Post-
conditioning During Primary Percutaneous Coronary Inter-
vention: the Effects of Post- Conditioning on Myocardial
Reperfusion in Patients With ST-Segment Elevation Myo-
cardial Infarction) trial in 700 patients undergoing primary
PCI demonstrated that ischemic post-conditioning with
4 cycles of 1 min of balloon inﬂation after restoration of
coronary blood ﬂow was not associated with improved
myocardial reperfusion.
Adenosine levels can rise rapidly in ischemic tissue due to
adenosine kinase inhibition, and this pathway is involved in
mediating ischemic pre-conditioning. To date, cyclosporine
is the most promising pharmacological post-conditioning
mimetic drug (72). Cyclosporine is thought to derive its
cardioprotective effects from inhibiting formation of the
mitochondrial permeability transition pore, a key component
of lethal reperfusion injury. The mitochondrial permeability
transition pore appears to form in the early stages of
reperfusion in response to the calcium overload and reactive
oxygen species generation that develops with reperfusion.
Paroxysmal supraventricular tachycardia. Therapeutically,
IV adenosine in a bolus dose of 6 to 12 mg (or higher) slows
AV nodal conduction and by this mechanism interrupts
re-entrant pathways involving the AV node and restores
sinus rhythm in most patients with supraventricular tachy-
cardia (73). Included in this group are typical AV nodalre-entrant tachycardia, AV reciprocating tachycardia with a
concealed bypass tract, and AV reciprocating tachycardia in
Wolff-Parkinson-White syndrome. Diagnostically, by cau-
sing transient AV block, adenosine may unmask atrial
ﬂutter/atrial ﬁbrillation (AF) and permit the correct diag-
nosis of broad complex tachycardias (73). Adenosine can
also terminate some ventricular tachycardias, particularly
those mediated by triggered activity (73).
Safety concerns and side effects of adenosine. As the half-
life of adenosine is brief, both its desired and unwanted
effects are generally short lived. Side effects are common
with adenosine and reﬂect the ubiquitous nature of adeno-
sine receptor expression. In general, they are more prevalent
with IV than with IC adenosine. In the Adenoscan study, a
large multicenter registry with >9,000 patients, examining
the safety and tolerability of IV adenosine infusion for stress
imaging studies, side effects due to adenosine were reported
in 81% of patients (74). Standard IV dosing via a peripheral
venous catheter was used. Commonly reported side effects
included ﬂushing (36.5%), dyspnea (35.2%), chest pain
(34.6%), gastrointestinal discomfort (14%), and headache
(11%). AV block and arrhythmias occurred in 7.6% and
3.3%, respectively. Bronchospasm occurred in 0.1% of the
study group. Importantly, there were no deaths in the cohort.
Side effects were more common in female patients, younger
patients, and those with a higher body mass index. Age
older than 70 years was the only independent predictor of
AV block after adenosine administration (74). Of note,
side effects reported in this study are far higher than those
reported in other studies and reﬂect the fact that the adeno-
sine infusion was continued for 6 min, which is longer than is
required for invasive physiology protocols. Furthermore, in a
study of 574 patients undergoing cardiac stress magnetic
resonance imaging, the incidence of side effects was much
lower (75). Chest pain and dyspnea were reported in only 14%
of the patient group, with nausea and vomiting in 5% (75).
Adenosine was infused for only 3 min at 140 mg/kg/min,
which could explain the disparate results compared with the
previously cited study. The incidence of patient-reported
side effects with a novel selective A2 agonist was still 73%,
with only a marginal improvement in symptom score when
directly compared with adenosine (see later) (76).
In patients with recent unstable coronary disease, non-
culprit lesions may be particularly difﬁcult to assess. On the
one hand, information from previous stress testing may be
lacking, and thus tools such as FFR could be particularly
useful; on the other hand, altered hemodynamics during
adenosine or side effects may be less well tolerated. How-
ever, despite such concerns, the use of adenosine, speciﬁcally
for patients undergoing comprehensive invasive coronary
physiological assessment appears safe (77–80).
Arrhythmias. Adenosine has proarrhythmic potential. AF is
well recognized (81) and in some reports is the most com-
mon arrhythmia (81). Adenosine is thought to provoke AF
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588through shortening of the atrial action potential duration. Its
incidence varies depending on the population being studied.
For example, in patients with known conductive system
disease undergoing electrophysiological assessment, the
incidence of AF was 12%. However, it is a rare occurrence in
the catheter laboratory and in noninvasive assessments (82).
In a retrospective dataset of 1,948 patients undergoing
adenosine stress myocardial perfusion studies, the incidence
of AF was 0.41% (83). AF was usually preceded by either
increasing atrial ectopy or signiﬁcant bradycardia. When AF
occurs, it is usually well tolerated unless associated with an
accessory pathway, where it may produce unstable arrhyth-
mias requiring direct current cardioversion (84).
Ventricular arrhythmias have also been reported with
adenosine. This is usually as a consequence of adenosine-
induced bradycardia and is more likely to occur in patients
with a propensity for bradycardia-related arrhythmias such
as those with a prolonged QTc interval (85).
The main contraindications to the use of adenosine infu-
sion are documented allergy to adenosine or severe asthma.
Inhaled adenosine monophosphate and ATP are known to
cause bronchospasm in asthmatics, most likely a result of
mast-cell mediator release (86). Despite case reports of
bronchospasm developing in asthmatic patients after adeno-
sine (87), these instances are very rare, and such an entity
requires distinguishing from themore frequently encountered
occurrence of benign dyspnea. Adenosine causes a sensation
of dyspnea in healthy patients but has not been shown to
objectively produce bronchospasm (88). This dyspnogenic
property has been proposed to be a result of direct stimulation
of pulmonary C ﬁbers by adenosine (88). In patients with
mild to moderate persistent asthma, the IV infusion of aden-
osine did not cause any signiﬁcant change in lung function
compared with placebo and healthy control groups. However,
asthmatic patients had a greater intensity of dyspnea in
response to adenosine. Thus, the use of IV adenosine in well-
controlled, mild to moderate asthma appears to be safe.
The presence of chronic obstructive pulmonary disease
has also been suggested as a contraindication to adenosine
use, but we and others believe that the use of IV adenosine
for mild to moderate airway disease, is safe (4). If chronic
obstructive pulmonary disease severity is a major concern,
then IC adenosine or an alternate agent can be used. When
using the IC route, bradycardia/transient AV block may be
observed, particularly at higher doses and when adminis-
tering into the right coronary artery (39). In most reported
cohorts, the incidence varies from 0% (22) to 16% (41) with
standard dosing.
Adenosine Interactions
Experimental data have conﬁrmed that methylxanthines
can cause an attenuated hyperemic response through
blockade of arteriolar A2a receptors (89). Caffeine (1,3,7trimethylxanthine) is thought to competitively inhibit the
adenosine receptor and thus may also attenuate the hyper-
emic response (90). This has been highlighted in animal
studies in which caffeine led to a blunted hyperemic vaso-
dilator response (91). One study suggested that increasing
the adenosine dose to 210 mg/kg/min abolished any caffeine
effect (92). Some earlier studies failed to show this rela-
tionship between caffeine and the hyperemic response, but
such studies tended to have lower caffeine concentrations
(93). Caffeine appears to have a dose-dependent afﬁnity for
the adenosine receptor, and this may explain these discor-
dant ﬁndings. Theophylline, a xanthine derivative com-
monly prescribed for reactive airway disease also antagonizes
adenosine and may need to be withheld before any imaging/
invasive assessment. We advocate the avoidance of caffeine
for at least 12 h in patients undergoing stress perfusion
imaging or invasive coronary ﬂow assessment if adenosine is
the hyperemic agent to be used. Furthermore, a full drug
history should be taken to make sure that there are no
potential interactions that could affect the hyperemic res-
ponse. Aminophylline and theophylline, both nonselective
adenosine antagonists, may be used in situations where the
effect of adenosine requires reversal. However, due to the
short half-life of adenosine, this is rarely required in a
catheter laboratory setting but is often used in myocardial
perfusion imaging where the longer acting dypyridamole is
used.
Novel Agents for Achieving Hyperemia
In addition to the agents that we have already mentioned,
there are new agents available to achieve hyperemia.
Regadenoson is a selective adenosine A2a receptor agonist
and in theory should produce hyperemic effects similar to
those of adenosine without the additional side effects often
seen with A1, A2b, and A3 receptor activation (94). It is
administered as an IV bolus and, because of its longer half-life
compared with adenosine (2 to 3 min), has a longer duration
of action. Importantly, there is similar efﬁcacy in terms of
the time taken to achieve hyperemia compared with aden-
osine (94). Regadenoson produces blood pressure–lowering
effects similar to adenosine but causes a signiﬁcantly higher
heart rate response. The adoption of regadenoson for per-
fusion imaging followed 2 large randomized studies showing
that it produced diagnostic information similar to that of a
standard adenosine infusion (76,95). Furthermore, although
side effects were common, they appeared to be fewer than
those reported in patients receiving adenosine. Because of its
A2a receptor selectivity, regadenoson appears to be safe in
patients with mild asthma (96). However, as yet there is a
lack of data to support its use in more severe forms of airway
obstruction.
Arumugham et al. (97) compared regadenoson with
adenosine for the assessment of FFR in 20 patients with
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589intermediate coronary stenoses and showed an excellent
correlation between the 2 drugs (r2 ¼ 0.93, p < 0.0001).
Furthermore, the minimal value of FFR appeared to be
achieved earlier with regadenoson compared with adenosine.
More recently, Prasad et al. (98) demonstrated that in 57
patients undergoing clinically indicated FFR assessment in
the catheter laboratory, regadenoson was as efﬁcacious as
adenosine for inducing hyperemia, with the FFR in both
groups being 0.79. There were fewer (but not statistically
signiﬁcantly fewer) side effects with regadenoson, and the
nadir to hyperemia was shorter in the regadenoson group.
Nicorandil, a drug with nitrate-like effects through its
increase in cyclic guanosine monophosphate and also Kþ
ATP channel modulation, was also compared with adeno-
sine in 210 patients with an intermediate coronary stenosis
(99). Hyperemic efﬁcacy was compared with IC and IV
adenosine versus IC nicorandil. The investigators found
that the hyperemic efﬁcacy of IC nicorandil (2 mg) was
noninferior to that of IV adenosine. There was also no sig-
niﬁcant difference between the index of microvascular resis-
tance with IV adenosine compared with IC nicorandil,
suggesting that similar levels of steady-state minimal resis-
tance were obtained with both drugs. Moreover, there were no
side effects/adverse reactions with nicorandil, whereas with
adenosine, AV block occurred in 12 patients with IC
administration and 4 patients with the IV administration (99).Conclusions
Adenosine has a critical role in the noninvasive and invasive
assessment of myocardial perfusion as well as having thera-
peutic efﬁcacy in patients with no-reﬂow. In the electro-
physiological setting, it has an important role in both
the diagnosis and treatment of a range of arrhythmias.
Although side effects are frequently reported, they are seldom
troublesome and due to the short half-life of the drug are
transient. Newer agents show promise but require further data
before they replace adenosine as a ﬁrst-line agent.
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